D0911 | equilin
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 24.34±4.60 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 31.62 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 39.15±15.51 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Danger |
Aggregated GHS information provided by 81 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H302 (19.75%): Harmful if swallowed [Warning Acute toxicity, oral] H312 (19.75%): Harmful in contact with skin [Warning Acute toxicity, dermal] H332 (19.75%): Harmful if inhaled [Warning Acute toxicity, inhalation] H351 (98.77%): Suspected of causing cancer [Warning Carcinogenicity] H360 (33.33%): May damage fertility or the unborn child [Danger Reproductive toxicity] H361 (66.67%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] H362 (32.1%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P260, P261, P263, P264, P270, P271, P280, P281, P301+P312, P302+P352, P304+P312, P304+P340, P308+P313, P312, P322, P330, P363, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| (11aS,6bS,8aS)-4-hydroxy-8a-methyl-2,7,8,10,11,11a,6b,8a-octahydrocyclopenta[1 ,2-a]phenanthren-9-one | (9S,13S,14S)-3-hydroxy-13-methyl-9,11,12,13,15,16-hexahydro-6H-cyclopenta[a]phenanthren-17(14H)-one | (9S,13S,14S)-3-hydroxy-13-methyl-9,11,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-17-one |
| 08O86EX0J4 | 1,3,5(10),7-Estratetraen-3-ol-17-one; | 1,3,5,7-Estratetraen-3-ol-17-one |
| 1,5,7-Estratetraen-3-ol-17-one | 3-HYDROXYESTRA-1,3,5(10),7-TETRAEN-17-ONE | 3-Hydroxy-1,3,5(10),7-estratetraen-17-one |
| 3-Hydroxyestra-1,3,5(10),7-tetraen-17-one (9CI) | 3-Hydroxyestra-1,5(10),7-tetraen-17-one | 3-Hydroxyoestra-1,3,5(10),7-tetraen-17-one |
| 3-hydroxy-estra-1,3,5(10), 7-tetraen-17-one | 3-hydroxy-estra-1,3,5(10),7-tetraen-17-one | 3-hydroxy-estra-1,3,5(10),7tetraen-17-one |
| 4-08-00-01366 (Beilstein Handbook Reference) | 474-86-2 | 7-Dehydroestrone |
| 7-Dehydroestrone | AKOS024285096 | BDBM50423544 |
| BPBio1_000923 | BRD-K04046242-001-03-6 | BRN 2624302 |
| BSPBio_000839 | C14392 | CAS-474-86-2 |
| CCG-220850 | CCRIS 9074 | CHEBI:42309 |
| CHEMBL323533 | CS-4786 | CTK4J0031 |
| D04041 | DB02187 | DSSTox_CID_27433 |
| DSSTox_GSID_47433 | DSSTox_RID_82343 | DTXSID7047433 |
| Dihydroequilenin | EINECS 207-488-6 | Equilin |
| Equilin (USP) | Equilin [USP] | Equilin solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material |
| Equilin, European Pharmacopoeia (EP) Reference Standard | Equilin, United States Pharmacopeia (USP) Reference Standard | Equilin, VETRANAL(TM), analytical standard |
| Estra-1,3,5(10),7-tetraen-17-one,3-hydroxy- | Estra-1,5(10),7-tetraen-17-one, 3-hydroxy- | FT-0632181 |
| HMS1570J21 | HMS2097J21 | HMS2233A16 |
| HMS3714J21 | HY-B1176 | LMST02010026 |
| MLS000028624 | MLS001148117 | NCGC00179406-01 |
| NCGC00256728-01 | NSC 10971 | NSC-10971 |
| NSC10971 | Opera_ID_780 | Prestwick0_000850 |
| Prestwick1_000850 | Prestwick2_000850 | Prestwick3_000850 |
| Prestwick_219 | Q5384492 | S00287 |
| SCHEMBL124758 | SMR000058656 | SPBio_002760 |
| SR-01000721841 | SR-01000721841-2 | ST081365 |
| Tox21_302641 | UNII-08O86EX0J4 | WKRLQDKEXYKHJB-HFTRVMKXSA-N |
| WLN: L E5 B666 FV JUTTT&J E1 OQ | ZINC100031739 | equilin |